What is suPAR?

suPAR is a protein measurable in blood. It reflects the immune system activation level, also known as inflammation. An elevated suPAR level is associated with the presence and severity of a broad range of acute and chronic health issues and short-term mortality. Contrary, a low suPAR level is associated with a good prognosis and indicates good health. All individuals have a base level of suPAR that increases with age but can be altered through timely disease management and lifestyle changes.

From acute care to longevity, suPARnostic® is a reliable prognostic tool that enables healthcare professionals to make quick and informed decisions.

What is your area of interest?

Learn more about how suPAR can be used to guide you clients

Hospital

Learn more about how suPAR can be used to support your clinical decisions

Learn how suPAR can be used to improve clinical trial efficiency

Triage suPARcharged

The suPAR biomarker predicts critical illness across diseases, by measuring the level of activation in the immune response. suPARnostic® is a reliable prognostic tool that enables healthcare professionals to make quick and informed patient triaging decisions at emergency departments in hospitals.

How to interpret suPAR results

Empowering clinical decisions

suPARnostic® empowers healthcare professionals to lead patient triage with confidence by making better-informed decisions backed by reliable biological data across diseases.

Implementing the biomarker suPAR in triage and clinical care delivers faster and safer patient discharges, reduces re-admissions, unnecessary admissions, as well as hospital length-of-stay. – Freeing up critical resources, valuable time, and saving hospital beds for those who need them. Incorporating suPAR in triage has benefits for patients, clinicians and Emergency Department.

suPARnostic® video

Improve patient care

Up to 22% reduction in hospital admissions and up to 6% reduction in hospital length-of-stay per patient

improve

Reduce healthcare costs

Up to €100-380 savings per admission depending on medical specialty and geography

reduce

Empower clinical staff

Get more information to make more confident decisions to potentially reduce uncertainty

empower

“it is essential to have the help of biomarkers, such as suPAR, which can support the discharge decision”

Juan González del Castillo,
Dr PhD, Hospital Clínico San Carlos, Spain
suPAR News Vol. 1, April 2019

How suPARnostic® works at the emergency department

Step 1

A patient is admitted to the emergency department for observation

Step 2

The patient’s blood sample is drawn

Step 3

The patient’s suPAR level is measured at the central lab
(~20 minutes) and fits existing hospital workflow.

Step 4

The physician gets the result and makes a triage decision

suPAR is a significant independent predictor of mortality of emergency department patients

AllsuPAR ≤ 4 ng/mLsuPAR > 4 and < 6 ng/mLsuPAR ≥ 6 ng/mlP Value
N1747804514429
Discharge < 24 H N785462215108< 0.001
30 Day pre-admitted N379131121127< 0.001
Readmission 30 Days N3681531141010,14
Mortality 7 Days N343922< 0.001
Mortality 30 Days N8162550< 0.001
Mortality 90 Days N13884387< 0.001

* Santeri, S., Peter, A.A., Kristiina, N. et al. suPAR cut-offs for stratification of low, medium, and high-risk acute medical patients in the emergency department. BMC Emerg Med 21, 149 (2021).

suPAR compared to other biomarkers


* suPAR values should be used in conjunction with clinical findings and the results of other laboratory parameters. suPAR values alone are not indicative of the need for mechanical ventilation.

1. Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia. Rovina N et al. Crit Care. 2020 4(1):187. (LINK: https://pubmed.ncbi.nlm.nih.gov/32354367/
2. Soluble Urokinase Receptor (SuPAR) in COVID-19-Related AKI. Azam TU et al. J Am Soc Nephrol. 2020 (LINK: https://pubmed.ncbi.nlm.nih.gov/32963090/
3. Soluble Urokinase-Guided Anakinra To Prevent Respiratory Failure In COVID-19: A Single-Arm Trial. Kyriazopoulou E et al. (preprint, link to be provided when available)
4. Soluble Urokinase Plasminogen Activator Receptor: A Biomarker for Predicting Complications and Critical Care Admission of COVID-19 Patients. Chalkias A et al. Mol Diagn Ther. 2020 (5):517-521. (LINK: https://pubmed.ncbi.nlm.nih.gov/32613288/
5. COVID-19 and pneumonia: a role for the uPA/uPAR system. D’Alonzo D et al. Drug Discov Today. 2020 (8):1528-1534. Review. (LINK: https://pubmed.ncbi.nlm.nih.gov/32562843/

1000+

published suPAR studies in leading medical journals

Nature Medicine Logo
Science Journal Logo
JAMA Pediatrics Logo

The suPARnostic® brand consists of 4 products:

Quick Triage

A Point of Care Solution

TurbiLatex

For Automated Systems

ELISA Assay

Clinical and Research

suPARnostic POC+

POC+

Point-of-care finger prick

New Webinar

Webinar

Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates